0001209191-19-020633.txt : 20190320
0001209191-19-020633.hdr.sgml : 20190320
20190320174929
ACCESSION NUMBER: 0001209191-19-020633
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170802
FILED AS OF DATE: 20190320
DATE AS OF CHANGE: 20190320
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Daniel Lee
CENTRAL INDEX KEY: 0001713712
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 19695448
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-08-02
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001713712
Flynn Daniel Lee
C/O DECIPHERA PHARMACEUTICALS, INC.
500 TOTTEN POND ROAD
WALTHAM
MA
02451
0
1
0
0
Chief Scientific Officer
Common Stock
2017-08-02
5
G
0
E
55270
0.00
D
0
I
See Footnote
Common Stock
2017-08-02
5
G
0
E
55270
0.00
A
147049
I
See Footnote
This transaction involved the transfer of the Reporting Person's interest in Biochenomix, LLC to the Daniel L. Flynn Irrevocable Trust. The Reporting Person's daughter is trustee of the trust and the Reporting Person's spouse is the sole lifetime beneficiary of the trust. Biochenomix, LLC holds 55,270 shares directly and the Daniel L. Flynn Irrevocable Trust holds 91,779 shares directly. The Reporting Person disclaims Section 16 beneficial ownership over all such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that the Reporting Person has beneficial ownership of such shares for Section 16 or for any other purposes.
/s/ Jeffrey M. Held, Attorney-in-Fact
2019-03-20